We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Telmisartan Better at Controlling Blood Pressure

By HospiMedica staff writers
Posted on 12 Jul 2006
A new meta-study shows that telmisartan provides superior, powerful blood pressure
reduction from morning to morning compared to other leading angiotensin II blockers.

Researchers from the University of Milano-Bicocca (Italy) examined a pooled analysis of over 5,100 patients with mild-to-moderate hypertension in 11 studies. More...
Ambulatory blood pressure monitoring (ABPM) readings over 24 hours were used to measure fluctuations in blood pressure reductions and to calculate smoothness index (SI) scores for telmisartan and other commonly used antihypertensives, including valsartan, losartan, ramipril, and amlodipine. The smoothness index, a potential indicator for the prevention of organ damage, is defined as the average of the 24 hourly blood pressure changes induced by treatment, divided by the corresponding standard deviation. A high SI score represents a blood pressure reduction that is meaningful and smooth.

The results of the ABPM and SI measurements showed that telmisartan, developed by Boehringer Ingelheim (Ingelheim, Germany), provides more effective blood pressure control over 24 hours compared to other leading angiotensin II receptor blockers (ARBs) and ramipril, and is comparable to amlodipine. The findings were presented at the annual meeting of the European Society of Hypertension (ESH), held in June 2006 in Madrid (Spain).

Uncontrolled blood pressure can lead to organ damage which includes the heart, vascular system, kidneys, and brain. Damage to these organs can cause long-term cardiovascular problems such as heart disease, heart attack, stroke, and even death,” said lead investigator Professor Gianfranco Parati. "More than half of the patients who appear to have well controlled blood pressure when checked in the doctor's office do not have it controlled over 24 hours. This is why the SI was developed to provide physicians with a more precise and clinically relevant alternative to single office blood pressure readings.”



Related Links:
University of Milano-Bicocca
Boehringer Ingelheim

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.